Top

Optie A:

Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
Optie B:

Deel de link per e-mail
Link delen

volgende artikel Trends in Psychotropic Medication Use for Medic...

Tip

Swipe om te navigeren naar een ander artikel

01-05-2014 | Original Paper | Uitgave 4/2014

Psychotropic Medication Use with Troubled Children and Youth

Tijdschrift:: Journal of Child and Family Studies > Uitgave 4/2014

Auteurs:: Jonathan C. Huefner, Annette K. Griffith

» Toegang tot de volledige tekst krijgen

Abstract

This article serves as an introduction to a Special Issue focused on the use of psychotropic medication with children and youth identified with psychiatric disorders and emotional and behavioral disturbance. In this editorial, we provide a brief summary of why research examining psychotropic medication use for children and youth is increasingly important and a brief background on what research to date has identified. We also provide a brief description of the manuscripts selected for inclusion in this Special Issue.

Log in om toegang te krijgen

Hier inloggen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Psychologie Totaal

Met BSL Psychologie Totaal blijf je als professional steeds op de hoogte van de nieuwste ontwikkelingen binnen jouw vak. Met het online abonnement heb je toegang tot een groot aantal boeken, protocollen, vaktijdschriften en e-learnings op het gebied van psychologie en psychiatrie. Zo kun je op je gemak en wanneer het jou het beste uitkomt verdiepen in jouw vakgebied.

Meer informatie

Coghill, D. R., Seth, S., Pedroso, S., Usala, T., Currie, J., & Gagliano, A. (in press). Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: Evidence from a systematic review and a meta-analysis. Biological Psychiatry. doi: 10.1016/j.biopsych.2013.10.005.

Comer, J. S., Olfson, M., & Mojtabai, R. (2010). National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007. Journal of the American Academy of Child and Adolescent Psychiatry, 49, 1001–1010. doi: 10.1016/j.jaac.2010.07.007. PubMedCentralPubMedCrossRef

Correll, C. U. (2008). Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. International Review of Psychiatry, 20, 195–201. doi: 10.1080/09540260801889179. PubMedCrossRef

Correll, C. U., Kratochvil, C. J., & March, J. S. (2011). Developments in pediatric psychopharmacology: Focus on stimulants, antidepressants, and antipsychotics. Journal of Clinical Psychiatry, 72, 655–670. doi: 10.4088/JCP.11r07064. PubMedCrossRef

Correll, C. U., Penzner, J. B., Parikh, U. H., Mughal, T., Javed, T., Carbon, M., et al. (2006). Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child and Adolescent Psychiatric Clinics of North America, 15, 177–206. doi: 10.1016/j.chc.2005.08.007. PubMedCrossRef

Harrison, J. N., Cluxton-Keller, F., & Gross, D. (2012). Antipsychotic medication prescribing trends in children and adolescents. Journal of Pediatric Health Care, 26, 139–145. doi: 10.1016/j.pedhc.2011.10.009. PubMedCentralPubMedCrossRef

Jensen, P. S., Buitelaar, J., Pandina, G. J., Binder, C., & Haas, M. (2007). Management of psychiatric disorders in children and adolescents with atypical antipsychotics: A systematic review of published clinical trails. European Child and Adolescent Psychiatry, 16, 104–120. doi: 10.1007/s00787-006-0580-1. PubMedCrossRef

March, J., Silva, S., Vitiello, B., & The TADS Team. (2006). The Treatment for Adolescents with Depression Study (TADS): Methods and message at 12 weeks. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1393–1403. doi: 10.1097/01.chi.0000237709.35637.c0. PubMedCrossRef

Mehler-Wex, C., Kölch, M., Kirchheiner, J., Antony, G., Fegert, J. M., & Gerlach, M. (2009). Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child and Adolescent Psychiatry and Mental Health, 3, 1–9. doi: 10.1186/1753-2000-3-14. CrossRef

Najjar, F., Welch, C., Grapentine, W. L., Sachs, H., Siniscalchi, J., & Price, L. H. (2004). Trends in psychotropic drug use in a child psychiatric hospital from 1991–1998. Journal of Child and Adolescent Psychopharmacology, 14, 87–93. doi: 10.1089/104454604773840526. PubMedCrossRef

Naylor, M. W., Davidson, C. V., Ortega-Piron, D. J., Bass, A., Gutierrez, A., & Hall, A. (2007). Psychotropic medication management for youth in state care: Consent, oversight, and policy considerations. Child Welfare, 86, 175–192. PubMed

Nevels, R. M., Dehon, E. E., Alexander, K., & Gontkovsky, S. T. (2010). Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: A review of current and potentially promising treatment options. Experimental and Clinical Psychopharmacology, 18, 184–201. doi: 10.1037/a0018059. PubMedCrossRef

Stigler, K. A., & McDougle, C. J. (2008). Pharmacotherapy of irritability in pervasive developmental disorders. Child and Adolescent Psychiatric Clinics of North America, 17, 739–752. doi: 10.1016/j.chc.2008.06.002. PubMedCrossRef

Swanson, J., Arnold, L. E., Kraemer, H., Hechtman, L., Molina, B., Hinshaw, S., et al. (2008). Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of children with ADHD (MTA): Part I: Executive summary. Journal of Attention Disorders, 12, 4–14. doi: 10.1177/1087054708319345. PubMedCrossRef

Tishler, C. L., & Reiss, N. S. (2012). Psychotropic drugs and paediatrics: A critical need for more clinical trials. Journal of Medical Ethics, 38, 250–252. doi: 10.1136/medethics-2011-100003. PubMedCrossRef

Vitiello, B. (2007). Research in child and adolescent psychopharmacology: Recent accomplishments and new challenges. Psychopharmacology (Berl), 191, 5–13. doi: 10.1007/s00213-006-0414-3. CrossRef

Vitiello, B. (2008). Recent developments and strategies in pediatric pharmacology research in the USA. Child and Adolescent Psychiatry and Mental Health, 2, 36. doi: 10.1186/1753-2000-2-36. PubMedCentralPubMedCrossRef

Vitiello, B., Rohde, P., Silva, S., Wells, K., Casat, C., Waslick, B., et al. (2006). Functioning and quality of life in the Treatment for Adolescents With Depression Study (TADS). Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1419–1426. doi: 10.1097/01.chi.0000242229.52646.6e. PubMedCrossRef

Zito, J. M., Safer, D. J., Sai, D., Gardner, J. F., Thomas, D., Coombes, P., et al. (2008). Psychotropic medication patterns among youth in foster care. Pediatrics, 121, 157–163. doi: 10.1542/peds.2007-0212. CrossRef

Titel: Psychotropic Medication Use with Troubled Children and Youth
Auteurs:: Jonathan C. Huefner
Annette K. Griffith
Publicatiedatum: 01-05-2014
DOI: https://doi.org/10.1007/s10826-014-9941-4
Uitgeverij: Springer US
Tijdschrift: Journal of Child and Family Studies
Uitgave 4/2014
Print ISSN: 1062-1024
Elektronisch ISSN: 1573-2843

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Tip

Swipe om te navigeren naar een ander artikel

Psychotropic Medication Use with Troubled Children and Youth

Abstract

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Psychologie Totaal

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Tip

Swipe om te navigeren naar een ander artikel

Abstract

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Psychologie Totaal

Andere artikelen Uitgave 4/2014

A. M. Heru: Working with Families in Medical Settings: A Multidisciplinary Guide for Psychiatrists and Other Health Professionals

A Review of Recent FDA Drug Safety Communications for Pediatric Psychotropics

Reducing Psychotropic Medications in an Intensive Residential Treatment Center

Use of Psychotropic Medications Among Youth in Treatment Foster Care

Medically Defining, Screening, and Treating Conduct Disorder: A French Controversy

Psychotropic Medication Patterns in Medicaid-Insured Youth Based on Clinician-Reported Maltreatment Status